Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-29
DOI
10.1007/s00262-020-02730-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas
- (2019) Takafumi Nakano et al. ORAL ONCOLOGY
- Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
- (2019) Dongxu Wang et al. Journal of Hematology & Oncology
- Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
- (2019) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- The expression of PD-L1 in salivary gland carcinomas
- (2019) Domenic Vital et al. Scientific Reports
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- (2019) Cristina P. Rodriguez et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma
- (2018) Roger B. Cohen et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
- (2018) Alberto Carretero-González et al. Oncotarget
- Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade
- (2018) Deepak Mittal et al. Cancer Discovery
- Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
- (2018) Marie-Léa Gauci et al. CLINICAL CANCER RESEARCH
- Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
- (2017) Liting Guo et al. Journal of Cancer
- PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
- (2016) Junzo Hamanishi et al. International Journal of Clinical Oncology
- Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas
- (2016) Takashi Mukaigawa et al. JOURNAL OF SURGICAL ONCOLOGY
- Pembrolizumab (Keytruda)
- (2016) Gerry Kwok et al. Human Vaccines & Immunotherapeutics
- Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence
- (2016) Joline S. J. Lim et al. Therapeutic Advances in Respiratory Disease
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now